Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case series reports that electrochemotherapy with intravenous bleomycin effectively resolved cutaneous mast cell tumors in four cats, showing no tumor recurrence during follow-up, except for new lesions in one cat, and minimal local toxicity.

This study observed that local injection of minoxidil effectively prevented Ara-C-induced alopecia in newborn rats, while topical application was ineffective.

This study found that minoxidil stimulates the Kir6.2/SUR2 potassium channel, leading to tumor growth arrest in an ovarian cancer xenograft model by disrupting mitochondrial function and inducing cell death.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

This study found that multiphoton microscopy imaging allows for detailed observation and quantitative analysis of collagen alterations in the progression of endometrial cancer, potentially offering a faster, more accurate method for early diagnosis compared to current protocols.

This study found that DKK1 and WNT10b are paracrine factors that modulate hair follicle stem cell differentiation inhibition, contributing to androgenetic alopecia by affecting Wnt signaling in androgen-sensitive dermal papilla cells after dihydrotestosterone stimulation.

This study identified new potential targets and indications for several marketed drugs using in silico profiling, suggesting opportunities for drug repositioning.

This study found that androgens downregulate BMP2 in dermal papilla cells, inhibiting hair follicle stem cell differentiation, while BMP2 addition may restore hair lineage differentiation through the Wnt/β-catenin pathway.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.

In this summary of needle mesotherapy's role in treating alopecia, the researchers highlight its use in delivering beneficial substances directly to the skin or hair follicles, showing hair loss reduction after one treatment and hair regrowth after several sessions, although contraindications exist for certain populations.

This article reviews clinical issues and dermatologist perspectives on managing periungual lesions in patients undergoing docetaxel chemotherapy, but it reports no new clinical outcomes.

This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.

In this study, researchers synthesized nine new nicotinamide derivative compounds and found that one, identified as N4, exhibited significant cytotoxic effects on MCF-7 breast cancer cells, while other derivatives demonstrated notable antibacterial, antifungal, and antibiofilm activities.

Minoxidil not effective in preventing chemotherapy-induced hair loss.

This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.

In this study, the researchers identified that perturbing both AKT1 and MDM2 significantly reduces epithelial-mesenchymal transition in melanoma, proposing Cialis and Finasteride as potential therapeutic candidates with favorable properties for managing aggressive melanoma.

This study found that targeting mTORC1 with rapamycin effectively inhibited skin tumor promotion in a mouse model, highlighting a potential target for cancer chemoprevention.

This study found that mitotane causes specific changes in cortisol metabolism, including increased excretion of certain metabolites, which may influence cortisol bioavailability without hindering early detection of adrenocortical carcinoma recurrence.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This study reports a case where cyclosporine effectively treated a 51-year-old woman with idiopathic follicular mucinosis resistant to other therapies, suggesting its potential as an option for refractory cases.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study found that the medicinal formula YH0618 may reduce toxicity from the chemotherapy drug doxorubicin, improving side effects like hair loss and organ damage, while maintaining its anti-cancer effects.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

In this study, researchers used computational modeling and virtual screening to identify two FDA-approved drugs, Tadalafil and Finasteride, that may effectively inhibit key proteins involved in melanoma progression, suggesting potential for new therapeutic strategies against aggressive melanoma.